Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Diverse Demyelinating Entity in Pediatric Patients

Basma Adel Ibrahim; Wasnaa Hadi Abdullah; Mushriq Abdullah Hussein; Rasha Sulaiman Abdulraheem

doi:10.54133/ajms.v9i2.2297

Authors

Basma Adel Ibrahim Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-8089-5216
Wasnaa Hadi Abdullah Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0003-1549-3824
Mushriq Abdullah Hussein Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-5381-7116
Rasha Sulaiman Abdulraheem Department of Pediatrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0001-6452-2121

DOI:

https://doi.org/10.54133/ajms.v9i2.2297

Keywords:

Autoimmune disease, Multiple sclerosis, MOGAD, Treatment

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an autoimmune demyelinating disorder characterized by antibodies targeting the myelin oligodendrocyte glycoprotein, a protein of the myelin sheath in the central nervous system. Increasingly recognized as a distinct clinical entity, MOGAD requires tailored treatment strategies and careful long-term monitoring, rather than being considered a variant of multiple sclerosis and neuromyelitis optica spectrum disorder. While acute episodes respond well to immunotherapy, relapses are common and require long-term management. Progress in immune-based and remyelination therapies offers hope for improving outcomes.

Downloads

Download data is not yet available.

References

Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Rev Neurol. 2019; 15(2):89-102. doi: 10.1038/s41582-018-0112-x. DOI: https://doi.org/10.1038/s41582-018-0112-x

Androutsou ME, Tapeinou A, Vlamis-Gardikas A, Tselios T. Myelin oligodendrocyte glycoprotein and multiple sclerosis. Med Chem. 2018;14(2):120–128. doi: 10.2174/1573406413666170906123204. DOI: https://doi.org/10.2174/1573406413666170906123204

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. DOI: https://doi.org/10.1016/S1474-4422(22)00431-8

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021; 20(9):762-772. doi: 10.1016/S1474-4422(21)00218-0. DOI: https://doi.org/10.1016/S1474-4422(21)00218-0

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, De Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflam. 2018;15(1):134. doi: 10.1186/s12974-018-1144-2. DOI: https://doi.org/10.1186/s12974-018-1144-2

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol. 2018;75(4):478-487. doi: 10.1001/jamaneurol.2017.4601. DOI: https://doi.org/10.1001/jamaneurol.2017.4601

Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, et al. EU pediatric MOG consortium consensus: Part 1–Classification of clinical phenotypes of pediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Pediatr Neurol. 2020;29:2-13. doi: 10.1016/j.ejpn.2020.10.006. DOI: https://doi.org/10.1016/j.ejpn.2020.10.006

Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017; 89(9):900-908. doi: 10.1212/WNL.0000000000004312. DOI: https://doi.org/10.1212/WNL.0000000000004312

Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, et al. Associations of pediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234-246. doi: 10.1016/S1474-4422(19)30488-0. DOI: https://doi.org/10.1016/S1474-4422(19)30488-0

De Mol CL, Wong YY, Van Pelt ED, Wokke BH, Siepman TA, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Multiple Sclerosis J. 2020;26(7):806-814. doi: 10.1177/1352458519845112. DOI: https://doi.org/10.1177/1352458519845112

Baumann M, Hennes EM, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Multiple Sclerosis J. 2016;22(14):1821-1829. doi: 10.1177/1352458516631038 DOI: https://doi.org/10.1177/1352458516631038

Cobo‐Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody–associated disease. Ann Neurol. 2021; 89(1):30-41. doi: 10.1002/ana.25909. DOI: https://doi.org/10.1002/ana.25909

Orlandi R, Mariotto S, Gajofatto A. Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. Multiple Sclerosis Relat Disord. 2022; 63:103884. doi: 10.1016/j.msard.2022.103884. DOI: https://doi.org/10.1016/j.msard.2022.103884

Tan K, Yeo T, Yong KP, Thomas T, Wang F, Tye J, et al. Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore—Epidemiology and evolution of an emerging subspecialty. Neurol Clin Neurosci. 2021;9(4):259-265. doi: 10.1111/ncn3.12479. DOI: https://doi.org/10.1111/ncn3.12479

Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, et al. Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Multiple Sclerosis J. 2023;29(4-5):530-539. doi: 10.1177/13524585231156736. DOI: https://doi.org/10.1177/13524585231156736

Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody–associated disease in the United Kingdom. JAMA Network Open. 2022;5(1):e2142780. doi: 10.1001/jamanetworkopen.2021.42780. DOI: https://doi.org/10.1001/jamanetworkopen.2021.42780

Senanayake B, Jitprapaikulsan J, Aravinthan M, Wijesekera JC, Ranawaka UK, Riffsy MT, et al. Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. J Neurol Neurosurg Psychiatry. 2019. doi: 10.1136/jnnp-2018-320243. DOI: https://doi.org/10.1136/jnnp-2018-320243

Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529. doi: 10.3389/fimmu.2017.00529. DOI: https://doi.org/10.3389/fimmu.2017.00529

Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostásy K, Berger T, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol. 2013;191(7):3594-3604. doi: 10.4049/jimmunol.1301296. DOI: https://doi.org/10.4049/jimmunol.1301296

Spadaro M, Winklmeier S, Beltrán E, Macrini C, Höftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84(2):315-328. doi: 10.1002/ana.25291. DOI: https://doi.org/10.1002/ana.25291

Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga AS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020; 95(2):e111-120. doi: 10.1212/WNL.0000000000009758. DOI: https://doi.org/10.1212/WNL.0000000000009758

Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143(5):1431-146. doi: 10.1093/brain/awaa102. DOI: https://doi.org/10.1093/brain/awaa102

Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, Zrzavy T, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain. 2013;136(6):1799-1815. doi: 10.1093/brain/awt110. DOI: https://doi.org/10.1093/brain/awt110

Machado-Santos J, Saji E, Tröscher AR, Paunovic M, Liblau R, Gabriely G, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141(7):2066-2082. doi: 10.1093/brain/awy151. DOI: https://doi.org/10.1093/brain/awy151

Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e9. doi: 10.1111/cen3.12041. DOI: https://doi.org/10.1212/WNL.0000000000000101

Denic A, Wootla B, Rodriguez M. CD8(+) T cells in multiple sclerosis. Expert Opin Ther Targets. 2013;17(9):1053-1066. doi: 10.1517/14728222.2013.815726. DOI: https://doi.org/10.1517/14728222.2013.815726

Pham-Dinh D, Mattei MG, Nussbaum JL, Roussel G, Pontarotti P, Roeckel N, et al. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci. 1993;90(17):7990-7994. doi: 10.1073/pnas.90.17.7990. DOI: https://doi.org/10.1073/pnas.90.17.7990

Xiang H, Cai M. Infections combined with myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and systematic review of the literature. Cureus. 2024;16(10):e71229. doi: 10.7759/cureus.71229. DOI: https://doi.org/10.7759/cureus.71229

Kim H, Lee EJ, Kim S, Choi LK, Kim K, Kim HW, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease. Neurol Neuroimmunol Neuroinflam. 2020;7(3):e708. doi: 10.1212/NXI.0000000000000708. DOI: https://doi.org/10.1212/NXI.0000000000000708

Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15(4):307-324. doi: 10.1016/j.autrev.2015.12.004. DOI: https://doi.org/10.1016/j.autrev.2015.12.004

Gaudioso CM, Mar S, Casper TC, Codden R, Nguyen A, Aaen G, et al. MOG and AQP4 antibodies among children with multiple sclerosis and controls. Ann Neurol. 2023;93(2):271-284. doi: 10.1002/ana.26502. DOI: https://doi.org/10.1002/ana.26502

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi: 10.1212/WNL.0000000000001729. DOI: https://doi.org/10.1212/WNL.0000000000001729

Hacohen Y, Rossor T, Mankad K, Chong WK, Lux A, Wassmer E, et al. ‘Leukodystrophy‐like’ phenotype in children with myelin oligodendrocyte glycoprotein antibody‐associated disease. Dev Med Child Neurol. 2018;60(4):417-423. doi: 10.1111/dmcn.13649. DOI: https://doi.org/10.1111/dmcn.13649

Gutman JM, Kupersmith M, Galetta S, Kister I. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures. J Neurol Sci. 2018;387:170-173. doi: 10.1016/j.jns.2018.01.042. DOI: https://doi.org/10.1016/j.jns.2018.01.042

Loos J, Pfeuffer S, Pape K, Ruck T, Luessi F, Spreer A, et al. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. 2020;267(6):1632-1642. doi: 10.1007/s00415-020-09755-x. DOI: https://doi.org/10.1007/s00415-020-09755-x

Huppke P, Rostasy K, Karenfort M, Huppke B, Seidl R, Leiz S, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Multiple Sclerosis J. 2013;19(7):941-946. doi: 10.1177/1352458512466317. DOI: https://doi.org/10.1177/1352458512466317

Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Multiple Sclerosis J. 2020;26(14):1854-1865. doi: 10.1177/1352458519893093. DOI: https://doi.org/10.1177/1352458519893093

Kim KH, Cho J, Cho KH, Shin HY, Kim SW. Anti-myelin oligodendrocyte glycoprotein antibody-positive encephalitis with seizure and unilateral cortical fluid-attenuated inversion recovery-hyperintense lesions. J Clin Neurol (Seoul, Korea). 2021;17(3):481. doi: 10.3988/jcn.2021.17.3.481. DOI: https://doi.org/10.3988/jcn.2021.17.3.481

Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, et al. Serial anti–myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. 2020;77(1):82-93. doi: 10.1001/jamaneurol.2019.2940. DOI: https://doi.org/10.1001/jamaneurol.2019.2940

Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019;266(10):2481-2487. doi: 10.1007/s00415-019-09440-8. DOI: https://doi.org/10.1007/s00415-019-09440-8

Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):534-536. doi: 10.1136/jnnp-2016-315094. DOI: https://doi.org/10.1136/jnnp-2016-315094

Anis S, Regev K, Pittock SJ, Flanagan EP, Alcalay Y, Gadoth A. Isolated recurrent myelitis in a persistent MOG positive patient. Multiple Sclerosis Relat Disord. 2019;30:163-164. doi: 10.1016/j.msard.2019.02.016. DOI: https://doi.org/10.1016/j.msard.2019.02.016

Martin K, Srikanth P, Kanwar A, Falardeau J, Pettersson D, Yadav V. Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Multiple Sclerosis Relat Disord. 2024;81:105130. doi: 10.1016/j.msard.2023.105130. DOI: https://doi.org/10.1016/j.msard.2023.105130

Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, et al. Brainstem and cerebellar involvement in MOG-IgG associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2022;93(8):837–843. doi: 10.1136/jnnp-2020-325121. DOI: https://doi.org/10.1136/jnnp-2020-325121

Parrotta E, Kister I. The expanding clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease in children and adults. Front Neurol. 2020;11:960. doi: 10.3389/fneur.2020.00960. DOI: https://doi.org/10.3389/fneur.2020.00960

Hamid SH, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018; 75(1):65-71. doi: 10.1001/jamaneurol.2017.3196. DOI: https://doi.org/10.1001/jamaneurol.2017.3196

Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflam. 2017;4(2):e322. doi: 10.1212/NXI.0000000000000322. DOI: https://doi.org/10.1212/NXI.0000000000000322

Goldman-Yassen A, Lee A, Gombolay G. Leptomeningeal enhancement in pediatric anti-myelin oligodendrocyte glycoprotein antibody disease, multiple sclerosis, and neuromyelitis optica spectrum disorder. Pediatr Neurol. 2024;153:125-130. doi: 10.1016/j.pediatrneurol.2024.01.026. DOI: https://doi.org/10.1016/j.pediatrneurol.2024.01.026

Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD: how it differs from and resembles other neuroinflammatory disorders. Am J Roentgenol. 2021;216(4):1031-1039. doi: 10.2214/AJR.20.24061. DOI: https://doi.org/10.2214/AJR.20.24061

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VS, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-137. doi: 10.1136/jnnp-2017-316880. DOI: https://doi.org/10.1136/jnnp-2017-316880

Han JY, Kim SY, Kim W, Kim H, Cho A, Choi J, et al. Phenotype of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease in Children. J Clin Neurol (Seoul, Korea). 2025;21(1):65. doi: 10.3988/jcn.2024.0276. DOI: https://doi.org/10.3988/jcn.2024.0276

Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358. doi: 10.3389/fneur.2023.1260358. DOI: https://doi.org/10.3389/fneur.2023.1260358

Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301-309. doi: 10.1001/jamaneurol.2018.4053. DOI: https://doi.org/10.1001/jamaneurol.2018.4053

Hacohen Y, Mankad K, Chong WK, Barkhof F, Vincent A, Lim M, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89(3):269-278. doi: 10.1212/WNL.0000000000004117. DOI: https://doi.org/10.1212/WNL.0000000000004117

Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617-627. doi: 10.1093/brain/aww350. DOI: https://doi.org/10.1093/brain/aww350

Yılmaz Ü. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children. Explor Neuroprotect Ther. 2024;4(1):38-54. doi: 10.37349/ent.2024.00069. DOI: https://doi.org/10.37349/ent.2024.00069

Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. 2021;144(8):2401-2415. doi: 10.1093/brain/awab102. DOI: https://doi.org/10.1093/brain/awab102

Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798. doi: 10.1038/s41598-018-33158-8. DOI: https://doi.org/10.1038/s41598-018-33158-8

Reich DS. Lucchinetti CF, Calabresi PA. Multiple Sclerosis. New Engl J Med. 2018;378:169-180. doi: 10.1056/NEJMra1401483. DOI: https://doi.org/10.1056/NEJMra1401483

Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137-145. doi: 10.1136/jnnp-2016-313300. DOI: https://doi.org/10.1136/jnnp-2016-313300

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflam. 2016;13(1):280. doi: 10.1186/s12974-016-0718-0. DOI: https://doi.org/10.1186/s12974-016-0718-0

Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C. Clinical and neuroimaging findings in MOGAD–MRI and OCT. Clin Exp Immunol. 2021;206(3):227-238. doi: 10.1111/cei.13641. DOI: https://doi.org/10.1111/cei.13641

Agrawal M, Shankar S, Bhatta S. Neuromyelitis optica spectrum disorder with negative aquaporin-4 antibodies and positive anti-myelin oligodendrocyte glycoprotein antibodies: a case report. Med J Armed Forces India. 2020;78(Suppl 1):S303–S307. doi: 10.1016/j.mjafi.2020.10.012. DOI: https://doi.org/10.1016/j.mjafi.2020.10.012

Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218. doi: 10.3389/fneur.2022.885218. DOI: https://doi.org/10.3389/fneur.2022.885218

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858-1869. doi: 10.1212/WNL.0000000000005560. DOI: https://doi.org/10.1212/WNL.0000000000005560

Siriratnam P, Huda S, Butzkueven H, van der Walt A, Jokubaitis V, Moni M. A comprehensive review of the advances in neuromyelitis optica spectrum disorder. Autoimmun Rev. 2023;22(6):103465. doi: 10.1016/j.autrev.2023.103465. DOI: https://doi.org/10.1016/j.autrev.2023.103465

Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83-97. doi: 10.1111/bpa.12099. DOI: https://doi.org/10.1111/bpa.12099

Popescu BG, Parisi JE, Cabrera-Gomez JA, Newell K, Mandler RN, Pittock SJ, et al. Absence of cortical demyelination in neuromyelitis optica. Neurology. 2010;75(23):2103-2109. doi: 10.1212/WNL.0b013e318200d80c. DOI: https://doi.org/10.1212/WNL.0b013e318200d80c

Saji E, Arakawa M, Yanagawa K, Toyoshima Y, Yokoseki A, Okamoto K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol. 2013;73(1):65-76. doi: 10.1002/ana.23721. DOI: https://doi.org/10.1002/ana.23721

Collongues N, Chanson JB, Blanc F, Steibel J, Lam CD, Shabbir A, et al. The Brown Norway opticospinal model of demyelination: does it mimic multiple sclerosis or neuromyelitis optica? Int J Dev Neurosci. 2012;30(6):487-497. doi: 10.1016/j.ijdevneu.2012.05.004. DOI: https://doi.org/10.1016/j.ijdevneu.2012.05.004

Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl MR, Dunn R, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009;206(6):1303-1316. doi: 10.1084/jem.20090299. DOI: https://doi.org/10.1084/jem.20090299

Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129(8):1953-1971. doi: 10.1093/brain/awl075. DOI: https://doi.org/10.1093/brain/awl075

Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J Neurol. 2008;255(Suppl 6):36-42. doi: 10.1007/s00415-008-6007-9. DOI: https://doi.org/10.1007/s00415-008-6007-9

Lai QL, Zhang YX, Cai MT, Zheng Y, Qiao S, Fang GL, et al. Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2021;14:17562864211054157. doi: 10.1177/17562864211054157. DOI: https://doi.org/10.1177/17562864211054157

Dos Passos GR, Oliveira LM, Da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217. doi: 10.3389/fneur.2018.00217. DOI: https://doi.org/10.3389/fneur.2018.00217

Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflam. 2018;15(1):302. doi: 10.1186/s12974-018-1335-x. DOI: https://doi.org/10.1186/s12974-018-1335-x

Voase S, Robertson NP. Diagnostic criteria for MOGAD. J Neurol. 2024;271(10):3690–3692. doi: 10.1007/s00415-024-12405-1. DOI: https://doi.org/10.1007/s00415-024-12405-1

RedenbaughV, FlanaganEP. Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurotherapeutics. 2022;19(3):808-822. doi: 10.1007/s13311-022-01206-x. DOI: https://doi.org/10.1007/s13311-022-01206-x

Rojas JI, Pappolla A, Patrucco L, Cristiano E, Miguez J, Liwacki S, et al. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina. Neurol Sci. 2023;44(1):281-286. doi: 10.1007/s10072-022-06409-w. DOI: https://doi.org/10.1007/s10072-022-06409-w

Lopez-Chiriboga S, Sechi E, Buciuc M, Chen JJ, Pittock SJ, Lucchinetti CF, et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder. JAMA Neurol. 2020;77(12):1575-1577. doi: 10.1001/jamaneurol.2020.3115. DOI: https://doi.org/10.1001/jamaneurol.2020.3115

Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-3138. doi: 10.1093/brain/awx276. DOI: https://doi.org/10.1093/brain/awx276

Kogel AK, Ladopoulos T, Schwake C, Kleiter I, Teegen B, Siems N, et al. Cognitive impairment, associated clinical factors, and MR volumetric measures in myelin oligodendrocyte glycoprotein-IgG–associated disease. Neurol Neuroimmunol Neuroinflamm. 2024;11(6):e200325. doi: 10.1212/NXI.0000000000200325. DOI: https://doi.org/10.1212/NXI.0000000000200325

Takai Y, Misu T, Fujihara K, Aoki M. Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Front Neurol. 2023;14:1209749. doi: 10.3389/fneur.2023.1209749. DOI: https://doi.org/10.3389/fneur.2023.1209749

Huda S, Whittam D, Jackson R, Karthikeayan V, Kelly P, Linaker S, et al. Predictors of relapse in MOG antibody-associated disease: a cohort study. BMJ Open. 2021;11(12):e055392. doi: 10.1136/bmjopen-2021-055392. DOI: https://doi.org/10.1136/bmjopen-2021-055392

Ibrahim BA, Hussein SA, Abdullah WH. Cognitive functions in children with type I diabetes. Wiad Lek. 2023;76(5 pt 1):944-950. doi: 10.36740/wlek202305108. DOI: https://doi.org/10.36740/WLek202305108

Alsaffar H, Abdullah WH, Hussein SA. Hypothyroidism in pediatric patients with Prader-Willi syndrome; Regular monitoring is recommended. Med J Babylon. 2022;19(2):123-125. doi: 10.4103/MJBL.MJBL_43_22. DOI: https://doi.org/10.4103/MJBL.MJBL_43_22

Alabedi RF, Alsaffar H, Ibrahim BA, Abdullah WH. An endocrine perspective of juvenile moyamoya syndrome/disease: A literature review. Med J Babylon. 2023;20(1):13-17. doi: 10.4103/MJBL.MJBL_247_22. DOI: https://doi.org/10.4103/MJBL.MJBL_247_22

Hussein SA, Ibrahim BA, Abdullah WH. Anti-N-methyl-D-aspartate receptor encephalitis in pediatrics: A review of clinical manifestations, treatment, and prognosis. Mustansiriya Med J. 2022;21(2):96–99. doi: 10.4103/mj.mj_6_22. DOI: https://doi.org/10.4103/mj.mj_6_22

Al-Gburi AJ, Al-Obaidi SR, Abdullah WH. Short-term outcomes among patients with subclinical hypothyroidism undergoing primary percutaneous coronary intervention. Ghana Med J. 2023;57(1):37-42. doi: 10.4314/gmj.v57i1.6. DOI: https://doi.org/10.4314/gmj.v57i1.6

Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Praticò AD, et al. Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200065. doi: 10.1212/NXI.0000000000200065. DOI: https://doi.org/10.1212/NXI.0000000000200065

Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol. 2023:1-19. doi: 10.1007/s00415-023-11737-8. DOI: https://doi.org/10.1007/s00415-023-11737-8

Forcadela M, Rocchi C, San Martin D, Gibbons EL, Wells D, Woodhall MR, et al. Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria. Neurol Neuroimmunol Neuroinflamm. 2023;11(1):e200183. doi: 10.1212/NXI.0000000000200183. DOI: https://doi.org/10.1212/NXI.0000000000200183

Andersen J, Brilot F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis. Semin Immunol. 2025;78:101944. doi: 10.1016/j.smim.2025.101944. DOI: https://doi.org/10.1016/j.smim.2025.101944